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Background: Reduced forced expiratory volume in 1 second (FEV1) and the ratio of FEV1 to forced vital capacity
(FVC) are strong predictors of mortality and lung function is higher among individuals with exceptional longevity.
However, genetic factors associated with lung function in individuals with exceptional longevity have not been
identified.
Method: We conducted a genome wide association study (GWAS) to identify novel genetic variants associated
with lung function in the Long Life Family Study (LLFS) (n = 3,899). Replication was performed using data from the
CHARGE/SpiroMeta consortia. The association between SNPs and FEV1 and FEV1/FVC was analyzed using a linear
mixed effects model adjusted for age, age2, sex, height, field center, ancestry principal components and kinship
structure to adjust for family relationships separately for ever smokers and never smokers. In the linkage analysis, we
used the residuals of the FEV1 and FEV1/FVC, adjusted for age, sex, height, ancestry principal components (PCs),
smoking status, pack-years, and field center.
Results: We identified nine SNPs in strong linkage disequilibrium in the CYP2U1 gene to be associated with FEV1
and a novel SNP (rs889574) associated with FEV1/FVC, none of which were replicated in the CHARGE/SpiroMeta
consortia. Using linkage analysis, we identified a novel linkage peak in chromosome 2 at 219 cM for FEV1/FVC
(LOD: 3.29) and confirmed a previously reported linkage peak in chromosome 6 at 28 cM (LOD: 3.33) for FEV1.
Conclusion: Future studies need to identify the rare genetic variants underlying the linkage peak in chromosome 6
for FEV1.
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Pulmonary function, as determined by spirometry, indi-
cates the physiological state of the airways and lung. Pul-
monary function measures such as forced expiratory
volume in one second (FEV1), forced vital capacity
(FVC) and the ratio of the two measures (FEV1/FVC)
are used to diagnose chronic obstructive pulmonary dis-
ease (COPD) and assist in the diagnosis of asthma,
which are major causes of death and morbidity world-
wide [1]. Reduced (FEV1) and forced vital capacity
(FVC), in healthy asymptomatic adults, are predictors of
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article, unless otherwise stated.independent of smoking history [2-9]. The Danish 1905
cohort study also showed that higher FEV1 and peak ex-
piratory flow (PEF) in nonagenarians to be associated
with lower mortality [10]. Due to the strong and consist-
ent association with mortality, pulmonary function has
been viewed as a biomarker of aging itself [11]. We have
previously shown that the prevalence of self-reported
COPD was 3 times lower in the Long Life Family Study
(LLFS) as compared to the other similarly aged cohorts
[12] suggesting that LLFS participants, who were se-
lected for exceptional familial longevity, may have better
lung function as compared to the general population.
These findings are supported by a previous study that
reported male offspring of long lived parents had higher
lung function as compared to those with short lived par-
ents [13]. Several studies have shown that pulmonaryntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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mates ranging from 38% for FEV1 to 37% for FEV1/FVC
[14-16]. However, the 26 genetic loci associated with
FEV1/FVC, FEV1 or both (23 loci associated with FEV1/
FVC and 10 loci associated with FEV1) [17-19] in gen-
ome wide association studies explain only around 3%
of the variance in FEV1/FVC and around 1.5% of the
variance in FEV1 [18]. Furthermore, the mean age of
Cohorts for Heart and Aging Research in Genomic Epi-
demiology (CHARGE)/SpiroMeta consortia was 55 years;
hence, it identified genes for lung function among older
adults. Since findings from the LLFS [12] and a previous
study [13] suggest that there may be genetic determi-
nants of lung function among exceptionally long lived
individuals and families, we conducted a genome wide
association and linkage study among participants of the
LLFS, a family based cohort of exceptional longevity, to
identify novel genetic determinants of lung function in
this unique sample.
Material and methods
Cohort description and study design
The LLFS study design has also been described in detail
previously [12]. Briefly, the LLFS is a family-based co-
hort study (n = 4,559) that enrolled long-lived probands
and their siblings (n = 1,445), their offspring (n = 2,329)
and spousal controls (n = 785) recruited from 3 U.S. field
centers (Boston University Medical Center in Boston
MA, Columbia College of Physicians and Surgeons in
New York City NY, and the University of Pittsburgh in
Pittsburgh PA) and the University of Southern Denmark
to identify genetic determinants of longevity in these
families. At the U.S. field centers, an initial recruitment
brochure was mailed to all people in the Center for
Medicare and Medicaid Services list of Medicare enrol-
lees who were ≥89 years old on January 1, 2005, were
not in end stage renal disease or hospice programs and
lived in zip codes within 3 hours driving distance of one
of the three U.S field centers. Mailings were conducted
in collaboration with CMS and the NIA via an Intra-
Agency Agreement. Study participants were also recruited
from the local communities using mailed brochures, post-
ers, web-based media and newspaper advertisements as
well as community presentations at churches and senior
centers. Additional mailing lists were obtained through
local government agencies or purchased public domain
lists from commercial vendors. The University of Southern
Denmark used the Danish National Register of Persons to
identify individuals who were ≥90 years during the study
recruitment period without any restrictions on residence
[20]. Only families who had the proband, at least one living
sibling, and one of their living offspring (minimum family
size of 3) with a Family Longevity Selection Score (FLoSS)
of 7 or higher that correlates well with later-observedlongevity [21] and gave informed consent and were willing
to participate in the interview and examination including
donating a blood sample were eligible to participate in this
study. This strategy led to the enrollment of families with
the greatest potential utility for phenotypic and genetic
studies of exceptional survival in families. All research was
performed in compliance with the Helsinki Declaration.
Written informed consent was obtained from all enrollees.
In a few cases of cognitive impairment, family members
were enrolled via proxy consent, provided that the par-
ticipant was able to express assent at the time of the
examination. This study was approved by the Institutional
Review Boards at all the institutions in the United States
of America and Denmark.
After excluding 15% of the participants due to presence
of non-European ancestry (n = 6), low quality spirometry
(defined as 2 or more acceptable spirometry maneuvers
with reproducibility within 250 mL) (n = 295), self-
reported pulmonary fibrosis (n = 11) obtained during an
in-person interview, history of lung volume reduction sur-
gery (n = 14), or missing genotypes (n = 344), a total of
3,889 participants were included in the present analysis.
Lung function measurements
The examinations were conducted in the home setting
with portable equipment by centrally trained and certi-
fied research assistants using a standardized protocol.
Lung function was measured with a portable spirometer
(EasyOne Diagnostic, NDD Medical Technologies, An-
dover, MA) following American Thoracic Society guide-
lines [22]. Calibration checks and the best 3 maneuvers
were reviewed centrally by one investigator. Only spir-
ometry tests with 2 or more acceptable maneuvers with
reproducibility within 250 mL were selected for further
data analyses.
Genotyping and imputation
The Human Omni chip 2.5 v1 (Illumina Inc., Ca), was used
to genotype all the LLFS participants at the Center for
Inherited Disease Research (CIDR). Ancestry principal
components (PCs), to control for population structure,
were produced with EIGENSTRAT [23] on 1,515 LLFS un-
related individuals using 120,093 tag SNPs, where in ad-
vance any SNPs with minor allele frequencies (MAF) <5%,
Hardy Weinberg Equilibrium (HWE) p <1E-06, and with
missing genotypes were excluded. Ancestry PCs produced
from unrelated subjects were expanded, within EIGENS
TRAT framework, to all members of LLFS. Genotype im-
putations were performed based on the cosmopolitan
phased haplotypes of 1000 Human Genome (1000HG, ver-
sion 2010–11 data freeze, 2012-03-04 haplotypes) using
MACH and MINIMACH [24,25] and a total of 38,045,518
SNPs were imputed. When MAF ≥ 0.05 and r2 > 0.3 for im-
puted SNP filters were applied to the hybrid dataset for
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6,522,421 (from a total of 38,245,546 SNPs), of which
1,204,935 SNPs were genotyped and 5,317,486 SNPs were
imputed.
Statistical analysis
The statistical models used to test the association be-
tween the GWAS SNPs and lung function (FEV1 and
FEV1/FVC) were identical to the models used by the
CHARGE/SpiroMeta consortia [18], except that the
LLFS study also included adjustment for kinship struc-
ture to facilitate replication of results in the CHARGE/
SpiroMeta consortia. We employed a linear mixed ef-
fects model which adjusted for age, age2, sex, height,
field center and ancestry PCs (PC1-20) in addition to
the kinship matrix. The adjusted phenotypic residuals
from these models (FEV1 and FEV1/FVC) were inverse
normal transformed to normally distributed z-scores.
These transformed residuals were then used as the pheno-
type for association testing under an additive genetic model,
separately for ever smokers and never smokers. The associ-
ations between individual SNPs the FEV1 (milliliters) and
FEV1/FVC (percent) were analyzed using a linear mixed
effects model with kinship structure [26,27] to adjust for
family relationships separately for ever smokers and never
smokers. The effect estimates and standard errors for ever-
smokers and never smokers were meta-analyzed using
inverse-variance weighting.
We used the same criteria as the CHARGE/SpiroMeta
consortia for assessing genetic associations [18]. All SNPs
that showed a borderline association (p < 5E-06) with FEV1
and FEV1/FVC in LLFS were evaluated for their associ-
ation with FEV1 and FEV1/FVC in the CHARGE/Spiro-
Meta consortia [18] using statistical models identical to
those described above (individual family-based studies
within the CHARGE/SpiroMeta did adjust for kinship
structure while other studies within the consortia did not
adjust for kinship structure). Finally, genotypes from both
LLFS and CHARGE/SpiroMeta were meta-analyzed using
METAL to evaluate the overall association between indi-
vidual SNPs and lung function in both studies. We also
evaluated the replication of previously reported GWAS hits
(from the CHARGE/SpiroMeta consortia) for FEV1 and
FEV1/FVC in the LLFS population using the statistical
models described above.
To calculate Identity by Descent (IBD) for the linkage
analyses, the ZAPLO program was used to estimate hap-
lotypes of SNPs in small regions (0.5 cM intervals) [28].
The deCODE map was used to approximate the cM po-
sitions [29]. We identified all SNPs in our GWAS scan
with no Mendel inconsistencies and an average pedigree
heterozygosity ≥0.1. Within each 0.5 cM interval we
used the first five such SNPs to construct a haplotype
and if there were fewer than 5, we took all such SNPs inthe interval. With the resulting haplotypes, IBD at 1 cM
intervals was estimated in the Loki program [30], which
does chromosome-wide IBD estimation in intact pedi-
grees. These IBD estimates were then used in the SOLAR
package [31] to conduct a variance-component linkage
analysis. In the linkage analysis, we used the residuals of
the FEV1 and FEV1/FVC phenotypes, adjusted for age,
sex, height, ancestry PCs, smoking status (current, former,
never), pack-years, and field center. The SOLAR package
was also used to estimate heritability and empirical p of
LOD.
Results
There were 1,734 (45%) male participants and 2155 (55%)
female participants with an average age of 68.6 years
(standard deviation: 15.2 years) and an average BMI of
27.13 kg/m2 (standard deviation: 4.79 Kg/m2). There were
2,203 (57%) never smokers, 1,403 (40%) former smokers
and 283 (3%) current smokers. The average number of
cigarettes smoked among former smokers was 20.26 pack
years (standard deviation: 22.07 pack years) while the aver-
age number of cigarettes smoked among current smokers
was 28.25 pack years (standard deviation:19.03 pack
years). There were 89 participants (2.3%) with self-
reported history of chronic obstructive pulmonary disease
(COPD) and 339 (8.7%) participants with self-reported
history of asthma, 123 (3.1%) participants with a self-
reported history of congestive heart failure and 11 (0.28%)
participants with a self reported history of lung cancer. As
shown in Table 1, the LLFS population was significantly
older (68.6 ± 15.2 years vs. 53.5 ± 7.7 years; p < 0.0001) and
had significantly higher percent never-smokers (57% vs.
42%; p < 0.0001) as compared to CHARGE/SpiroMeta
consortia. In addition, LLFS had slightly lower FEV1
(2455 ml vs. 2963; p < 0.0001) and FEV1/FVC (0.76 vs.
0.78; p < 0.0001) as compared to the CHARGE/SpiroMeta
consortia (Table 1).
We evaluated 6,522,421 SNPs across 3,889 individuals.
The Q-Q plots for FEV1 and FEV1/FVC are shown in
Additional file 1: Figures S1a and S1b respectively, while
the Manhanttan plots for FEV1 and FEV1/FVC are
shown in Additional file 1: Figures S2a and S2b respec-
tively. Overall, we found 130 SNPs (23 genotyped SNPs
and 107 imputed SNPs) that showed borderline associ-
ation with FEV1 (p < 5E-06) (Additional file 2: Table S1)
and 74 SNPs (14 genotyped SNPs and 60 imputed SNPs)
that showed borderline association with FEV1/FVC
(p < 5E-06) (Additional file 2: Table S2). There was one
SNP, rs71374110 in the ANKRD11 gene that showed a
borderline association with both FEV1 and FEV1/FVC
(Additional file 2: Tables S1 and S2). Among the GWAS
SNPs with borderline association, 49 SNPs for FEV1 and
28 SNPs for FEV1/FVC were available for replication in
the CHARGE/SpiroMeta dataset (Additional file 2: Tables
Table 1 Comparison of demographic and lung function variables* in LLFS and CHARGE/SpiroMeta consortia+
LLFS (n = 3889) CHARGE/SpiroMeta (n = 48201) p value
Age (years) 68.6 (15.2) 53.5 (7.7) <0.0001
Sex (% Male) 44 44 0.62
Smoking Status (% never smoker) 56.6 42.0 <0.0001
FEV1 (ml) 2455 (866) 2963 (798) <0.0001
FEV1/FVC 0.76 (0.07) 0.78 (0.09) <0.0001
*Values are means (standard deviations in parentheses) or percentages.
+Values for the demographic and lung function variables in the CHARGE/SpiroMeta consortia were calculated using previously published data (Additional file 2:
Table S1 a in Soler Artigas et al.) [18].
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with p <9.0E-07 are presented in Tables 2 and 3 and the
data for all SNPs are presented in Additional file 2: Tables
S1 and S2. As shown in Table 2, rs1493131 in the CYP2U1
gene showed borderline association with FEV1 (p = 7.4E-
07). In addition, 7 imputed SNPs in the CYP2U1 gene and
1 imputed SNP in the PHACTR2 gene also showed a bor-
derline association with FEV1 (p < 9.2E-07). However, none
of these SNPs were associated with FEV1 in the CHARGE/
SpiroMeta consortia or in the overall meta-analysis. Five of
the 9 previously identified GWAS SNPs (p < 1E-07) for
FEV1 were nominally associated with FEV1 in LLFS
(p < 0.05) (Additional file 2: Table S5). For FEV1/FVC, one
SNP, rs889574 in the ANKRD11 gene, demonstrated a bor-
derline association (p = 1.6E-07) in the LLFS GWAS,
(Table 3). Seven of 22 previously identified GWAS SNPs
(p < 1E-07) were also associated with FEV1/FVC in the
LLFS (p < 0.05) (Additional file 2: Table S6). A complete list
of all SNPs associated with lung function (p < 5E-06) is
shown in Additional file 2: Tables S1 and S2, with their an-
notation and quality control information.
The heritability of FEV1 and FEV1/FVC as estimated by
the SOLAR package was 0.37 ± 0.043 and 0.34 ± 0.040 re-
spectively in the LLFS. The highest LOD score obtained
for FEV1 was 3.33 localized to 28 cM (chr 6: 9275152 bp –
9467267 bp) at the q terminus of chromosome 6 (Figure 1).
This locus remained significant (LOD= 3.18) even after ad-
justment for 3 GWAS SNPs/indels located between
26 cM-34 cM on chromosome 6 and were nominally asso-
ciated with FEV1 (p < 0.001) (Additional file 2: Table S7). A
more comprehensive adjustment for 19 GWAS SNPs that
were nominally associated with FEV1 (p < 1E-03) over a
larger range (10 cM – 50 cM) further attenuated the link-
age peak (LOD = 2.60) but did not completely explain the
linkage peak (Additional file 2: Table S7). The highest
LOD score obtained for FEV1/FVC was 3.29 localized
to 219 cM in chromosome 2 (chr 2: 217963480 bp –
218313210 bp) (Figure 2). This locus did not remain sig-
nificant (LOD =2.2) after adjustment for 10 GWAS SNPs
located between 217 cM −236 cM nominally associated
with FEV1/FVC (p < 0.001) (Additional file 2: Table S7)
and was almost completely explained (LOD: 1.01) by ad-
justment of GWAS SNPs (n = 38) in a broad region from200–250 cM that were associated with FEV1/FVC (p <
0.001) (Additional file 2: Table S7). Further adjustment
for additional covariates such as age2, height2, BMI, for
self-reported COPD/asthma and those who took asthma/
COPD/bronchitis medications did not significantly change
results of the linkage analyses Additional file 1: Figures
S3a and S3b.
Discussion
This study identified a novel linkage peak in chromo-
some 2 for FEV1/FVC and confirmed a previously iden-
tified linkage peak in chromosome 6 for FEV1. This
study also replicated some of the GWAS SNPs identified
in previous studies. Though this study identified SNPs in
the CYP2U1 and PHACTR2 genes that were associated
with FEV1, these findings could not be replicated in in-
dependent datasets.
Two previous reports identified a linkage peak for FEV1
at the same locus (chromosome 6 at 28 cM (~280 kb)) as
the present study [32,33]. As compared to previous lin-
kage studies we had improved marker density (average
marker spacing = 0.5 cM) and improved accuracy by using
haplotype-based IBD estimation. The availability of
GWAS data also allowed us to evaluate whether GWAS
SNPs under the linkage peak explained the linkage peak
identified for FEV1. While we found a modest attenuation
of the FEV1 linkage peak after adjustment for common
GWAS SNPs under the linkage peak that were nominally
associated with FEV1 (p < 0.001), they did not completely
explain the linkage peak. In contrast, the novel linkage
peak identified in chromosome 2 at 219 cM (~372 kb) for
FEV1/FVC was almost completely explained, by adjust-
ment for the common GWAS SNPs under the linkage
peak that were nominally associated with FEV1/FVC
(p < 0.001). These findings suggest that common variants
alone are insufficient to explain some linkage peaks such
as the linkage peak in chromosome 6 for FEV1. As shown
in other diseases, the inability to identify association under
linkage peaks could in part be attributable to the fact that
only common variants are examined under the linkage
peak whereas the linkage signal could be caused by mul-
tiple rare variants with higher penetrance [34]. Hence, the
contribution of multiple rare variants with high penetrance
Table 2 GWAS findings for FEV1 in the LLFS (p <1E-07) and replication in the CHARGE/SpiroMeta consortia
LLFS CHARGE/SPIROMETA CONSORTIA META ANALYSIS
SNP Chromosomal
position
Gene Coded/non-
coded allele
Coded allele
frequency
β (SE) P_value Coded allele
frequency
β (SE) P_value Coded allele
frequency
β (SE) P_value HetPVal N
rs9390140 Chr 6: 144127026 PHACTR2 C/G 0.33 −0.121
(0.025)
8.83E-07 0.33 0.002
(0.008)
0.78 0.33 −0.008
(0.007)
0.25 1.80E-06 51073
rs1493126 Chr 4:108855828 CYP2U1 C/G 0.23 0.139
(0.028)
8.24E-07 0.22 −0.005
(0.009)
0.53 0.22 0.007
(0.008)
0.42 9.48E-07 51687
rs4956031* Chr4: 108857140 CYP2U1 T/C 0.23 0.138
(0.028)
9.17E-07 0.22 −0.005
(0.009)
0.52 0.22 0.007
(0.008)
0.43 1.04E-06 51715
rs998405 Chr4: 108862837 CYP2U1 C/G 0.23 0.139
(0.028)
7.93E-07 0.22 −0.006
(0.009)
0.50 0.22 0.006
(0.008)
0.43 8.18E-07 51501
rs17564501 Chr4: 108863209 CYP2U1 A/C 0.77 −0.139
(0.028)
7.93E-07 0.78 0.006
(0.009)
0.50 0.78 −0.006
(0.008)
0.44 8.15E-07 51456
rs1493122 Chr4: 108864651 CYP2U1 T/C 0.77 −0.139
(0.028)
7.59E-07 0.79 0.006
(0.009)
0.47 0.78 −0.006
(0.008)
0.46 7.40E-07 51105
rs1493131* Chr4: 108860906 CYP2U1 A/G 0.23 0.139
(0.028)
7.37E-07 0.22 −0.006
(0.009)
0.47 0.22 0.006
(0.008)
0.46 7.23E-07 51877
rs11724895 Chr4: 108865791 CYP2U1 C/G 0.77 −0.139
(0.028)
7.72E-07 0.79 0.006
(0.009)
0.46 0.78 −0.006
(0.008)
0.47 8.06E-07 51068
rs17564543 Chr4: 108863481 CYP2U1 T/C 0.77 −0.138
(0.028)
9.07E-07 0.78 0.007
(0.009)
0.40 0.78 −0.005
(0.008)
0.53 7.47E-07 50935
*These SNPs were genotyped using the Human Omni chip 2.5 v1 (Illumina Inc., Ca). Other SNPs were imputed.
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Table 3 GWAS findings for FEV1/FVC in the LLFS (p <1E-07) and replication in the CHARGE/SpiroMeta consortia
LLFS CHARGE/SPIROMETA CONSORTIA META ANALYSIS
SNP Chromosomal
position
Gene Coded/non-
coded allele
Coded allele
frequency
β (SE) P_value Coded allele
frequency
β (SE) P_value Coded allele
frequency
β (SE) P_value HetPVal N
rs889574* Chr16: 89386808 ANKRD11 T/C 0.31 0.129
(0.025)
1.63E-07 0.34 0.003
(0.007)
0.67 0.66 −0.013
(0.007)
0.06 9.99E-07 50425
*These SNPs were genotyped using the Human Omni chip 2.5 v1 (Illumina Inc., Ca). Other SNPs were imputed.
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Figure 1 Linkage peaks on chromosome 6 associated with FEV1 before and after adjustment for GWAS SNPs under the linkage peak
associated with FEV1. Original linkage is in red, the linkage in blue is for adjustment of GWAS SNPs (n = 3) in a narrow region from 26–34 cM
that were associated with p < 1E-03, and green is the linkage after adjustment of GWAS SNPs (n = 19) in a broad region from 10–50 cM that were
associated with p < 1E-03.
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in future studies. The linkage peak identified in chromo-
some 6 at 28 cM (~280 kb) for FEV1 does not contain any
known genes. However, there are several DNase I hyper-
sensitivity sites and putative transcription factor binding
sites (9H3K27Ac marks) that have been identified in cells
from pulmonary epithelium and blood vessels derived from
the pulmonary artery within this linkage peak (EnCode
data) suggesting that regulatory elements in this region
may play an important role in determining lung function.
The linkage peak for FEV1/FVC in chromosome 2 at
219 cM (~373 kb) contains the genomic region that codes
for the DIRC3 gene, a non coding RNA that is involved inFigure 2 Linkage peaks on chromosome 2 associated with FEV1/FVC
peak associated with FEV1/FVC. Original linkage is in red, the linkage in b
217–236 cM that were associated with p < 1E-03, and green is the linkage
200–250 cM that were associated with p < 1E-03.the pathogenesis of familial renal cancers (EnCode data).
Though DIRC3 is expressed in pulmonary tissue its role
in determining lung function has not been evaluated. Fur-
thermore, this region also contains DNase I hypersensi-
tivity sites or putative transcription factor binding sites
(9H3K27Ac marks) in cells derived from the pulmonary
epithelium or vasculature. Thus the linkage peaks identi-
fied in this study on chromosomes 2 and 6 may indicate
previously unidentified regulatory pathways that may in-
fluence longevity through their effect on lung function.
Though this study identified a few novel GWAS SNPs
that were associated with FEV1 and FEV1/FVC, none of
these findings could be replicated in the CHARGE/Spirobefore and after adjustment for GWAS SNPs under the linkage
lue is for adjustment of GWAS SNPs (n = 10) in a narrow region from
after adjustment of GWAS SNPs (n = 38) in a broad region from
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with FEV1 or FEV1/FVC in LLFS were available for repli-
cation in the CHARGE/SpiroMeta consortia. Thus, the
remaining SNPs and insertion/deletions polymorphisms
associated with FEV1 and FEV1/FVC in LLFS but not ge-
notyped/imputed in the CHARGE/SpiroMeta consortia
will need to be evaluated in future studies. Since the LLFS
study participants were not randomly selected to repre-
sent the general population but were specifically selected
for their family history of exceptional longevity, it is pos-
sible that there may be some unique genotypes associated
with lung function that may not be replicated in studies
that are more representative of the general population.
One previous study showed that elderly male offspring
(range: 65–89 years) with long lived parents (age at death
of at least on parent >80 years) had FEV1 that was 330 ml
larger than FEV1 for male offspring with short lived par-
ents even after controlling for smoking [13]. The findings
of the present study along with previous findings [13]
might indicate that long lived families have unique genetic
variants that contribute to higher lung function among
those with exceptional longevity. This study also repli-
cated 12 of 31 GWAS hits for FEV1 and FEV1/FVC identi-
fied in previous meta-analysis (Additional file 2: Tables S5
and S6). The reasons for not confirming all previously
identified variants in this study may include limited power,
population specific genetic heterogeneity and differences
in environmental exposures such as smoking. Genetic het-
erogeneity in contribution towards determination of lung
function in elderly participants (average age among LLFS
participants: 68.8 years) as compared to middle aged
adults may also contribute to the differences in genetic as-
sociation observed in the LLFS study as compared to pre-
vious studies. As shown in Additional file 2: Tables S3 and
S4, several SNPs had highly significant p for heterogeneity
between the LLFS and the CHARGE/SpiroMeta dataset
supporting the idea that, at least for some loci, heterogen-
eity in genetic contribution may account for the lack of
replication of certain loci.
Conclusion
The family-based cohort design of the LLFS with exten-
sive genotype information and detailed lung function mea-
surements makes this study a valuable resource to identify
genetic determinants of lung function. In addition to con-
firming some of the previously identified GWAS SNPs
and a previously identified linkage peak in chromosome 6
for FEV1, this study also identified a novel linkage peak in
chromosome 2 for FEV1/FVC. Repeated measurements of
lung function in this study population along with targeted
resequencing under the observed linkage peaks in future
studies may help clarify the role of genetic variants in de-
termining preserved lung function among exceptionally
long lived individuals.Additional files
Additional file 1: Supplementary Figures for lung function-RespR.
Figure S1a; Figure S1b; Figures S2a; Figure S2b; Figure S3a; Figure S3b.
Quality control for genotyped SNPs; Q-Q plot showing distribution of
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